头孢菌素类药物市场：依代、类型、剂型、适应症、通路及地区划分。

预计到2026年，头孢菌素类药物市场规模将达218.7亿美元，2033年将达到236.5亿美元。 2026年至2033年期间的复合年增长率预计为3.76%。

头孢菌素是一类频谱半合成β-内酰胺类抗生素，常用于治疗细菌感染疾病，如细菌性脑膜炎、中耳炎、肺炎、结核病、上呼吸道感染疾病、眼部感染、鼻窦炎、尿道感染感染疾病、皮肤感染疾病和性行为感染感染。最常用的头孢菌素包括头孢氨芐、头孢曲松、头孢克肟、头孢地尼和头孢克洛。在撒哈拉以南非洲国家，例如衣索比亚、加纳、奈及利亚和塞内加尔，由于医疗设施和基础设施落后，细菌感染疾病十分普遍，因此头孢菌素市场具有巨大的潜力。例如，根据世界卫生组织（世卫组织）2018年2月的报告，从西部的塞内加尔到东部的衣索比亚，撒哈拉以南非洲地区的细菌感染负担最为沉重。该地区每年仍有约3万例细菌感染病例报告。

市场动态

全球呼吸道感染疾病发病率的上升预计将推动头孢菌素类药物市场的成长。例如，根据2017年《全球呼吸道疾病影响》报告，下呼吸道感染疾病和肺炎是两大主要死因，每年造成超过400万人死亡。此外，2015年，肺炎导致920,136名五岁以下儿童死亡，占该年龄组所有死亡人数的15%。肺炎链球菌仍是肺炎最常见的致病菌，2015年导致393,000名五岁以下儿童死亡。

然而，美国食品药物管理局（FDA）召回次数的增加等因素正在阻碍头孢菌素类药物市场的成长。例如，2019年6月，鲁宾有限公司（Lupin Limited）从美国市场召回了18,604瓶（60毫升）用于治疗细菌感染疾病的头孢地尼（头孢菌素）口服悬浮液。此外，该公司于2019年1月宣布，由于违反现行药品生产品质管理规范（CGMP），在美国召回了287,784瓶头孢地尼口服悬浮液。

本次调查的主要特点。

• 本报告指出了各个细分市场的潜在商机，并说明了该市场中具有吸引力的投资提案矩阵。
• 此外，本研究还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
• 本报告根据以下参数提供全球头孢菌素药物市场主要企业的概况：公司概况、财务表现、产品系列、地理分布、分销策略、主要发展和策略。
• 透过利用本报告中的见解，企业行销负责人和经营团队可以就未来的产品发布、政府倡议、技术升级、市场扩张和行销策略做出明智的决策。
• 本报告旨在为行业内的各种相关人员提供参考，包括头孢菌素药物市场的投资者、产品製造商、经销商、供应商、研究和咨询公司、新参与企业和金融分析师。

目录

第一章：研究目标与前提条件

• 研究目标
• 前提
• 简称

第二章 市场范围

• 报告摘要
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章：市场动态、监管与趋势分析

• 市场动态
• 促进因素
• 阻碍因素
• PEST分析
• 波特五力分析
• 市场机会
• 法规环境
• 主要进展
• 产业趋势

第四章 全球头孢菌素类药物市场：按代划分，2026-2033年

• 第一代头孢菌素
• 第二代头孢菌素
• 第三代头孢菌素
• 第四代头孢菌素
• 第五代头孢菌素

第五章 全球头孢菌素类药物市场：按类型划分，2026-2033年

• 品牌
• 非专利的

第六章 全球头孢菌素类药物市场：以剂型划分，2026-2033年

• 口服药物
• 药片
• 胶囊
• 液体
• 注射药物

第七章 全球头孢菌素类药物市场：依适应症划分，2026-2033年

• 呼吸道感染疾病
• 皮肤感染疾病
• 耳部感染疾病
• 细菌感染疾病
• 尿道感染
• 性行为感染传染病
• 鼻窦炎
• 手术预防
• 其他的
• 脑膜炎
• 急腹症
• 骨盆腔感染疾病

第八章 全球头孢菌素类药物市场：依分销管道划分，2026-2033年

• 医院药房
• 零售药房
• 网路药房

第九章 全球头孢菌素类药物市场：依地区划分，2026-2033年

• 北美洲
  • 我们
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
• 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韩国
  • 亚太其他地区
• 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东国家
• 非洲
  • 南非
  • 北非
  • 中非

第十章 竞争格局

• 热图分析
  • Market Share Analysis（3x3 Matrix）
  • 公司简介
  • Merck &Co. Inc.
• GlaxoSmithKline Plc
  • Pfizer Inc.
• Allergan plc.
  • Abbott Laboratories
• Basilea Pharmaceutica Ltd.
  • Sanofi SA
• 罗氏製药
  • Lupin Limited
• 梯瓦製药工业公司
  • B. Braun Melsungen AG.

第十一章 分析师建议

• 机会
• 分析师意见
• Coherent Opportunity Map

第十二章

• 参考
• 调查方法

Cephalosporin Drugs Market is estimated to be valued at USD 21.87 Bn in 2026 and is expected to reach USD 23.65 Bn by 2033, growing at a compound annual growth rate (CAGR) of 3.76% 2025 To 2032 from 2026 to 2033.

Cephalosporin drugs are a group of broad-spectrum, semi-synthetic beta-lactam antibiotics generally used for the treatment of bacterial infections such as bacterial meningitis, otitis media, pneumonia, tuberculosis, upper respiratory tract infection, eye infections, sinusitis, urinary tract infections, skin infections, and sexually transmitted diseases. Most commonly used cephalosporin are cephalexin, ceftriaxone, cefixime, cefdinir, and cefaclor. The cephalosporin drugs market holds a huge potential in the sub-Saharan countries of Africa such as Ethiopia, Ghana, Nigeria, and Senegal, as these countries have high prevalence of bacterial infections due to underdeveloped healthcare facilities and infrastructure. For instance, according to the World Health Organization's (WHO) report of February 2018, the highest burden of this disease is in the belt of sub-Saharan Africa, stretching from Senegal in the west to Ethiopia in the east. Around 30,000 cases are still reported each year from that area.

Market Dynamics

Increasing prevalence of respiratory tract infections worldwide is expected to boost the cephalosporin drugs market growth. For instance, according to the report of The Global Impact of Respiratory Disease in 2017, lower respiratory tract infection and pneumonia are two of the leading causes of death, accounting for over 4 million fatalities, annually. Furthermore, pneumonia killed 920,136 children aged under 5 years in 2015, accounting for 15% of the deaths in this age group. Streptococcus pneumoniae remains the most frequent bacterial cause of pneumonia, accounting for deaths of 393,000 children aged under 5 years in 2015.

However, factors such as increasing Food and Drug Administration (FDA) recalls is hindering the cephalosporin drugs market growth. For instance, in June 2019, Lupin Limited recalled 18,604 bottles (60 ml) of Cefdinir (Cephalosporin) for Oral Suspension, used for the treatment of bacterial infections, from the U.S. market. Furthermore, in January 2019, the company announced recall of 287,784 bottles of Cefdinir for Oral Suspension in the U.S. due to CGMP (Current Good Manufacturing Practice) deviations.

Key features of the study

• This report provides in-depth analysis of the cephalosporin drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2019 - 2026, considering 2018 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global cephalosporin drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include, Merck & Co. Inc., GlaxoSmithKline plc., Pfizer Inc., Allergan plc., Abbott Laboratories, Basilea Pharmaceutica Ltd., Sanofi S.A., F. Hoffmann-La Roche AG, Lupin Limited, Teva Pharmaceutical Industries Ltd., and B. Braun Melsungen AG
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The global cephalosporin drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for cephalosporin drugs market, research and consulting firms, new entrants, and financial analysts

Market Segmentation

• By Generation
  • First-generation Cephalosporin
  • Second-generation Cephalosporin
  • Third-generation Cephalosporin
  • Fourth-generation Cephalosporin
  • Fifth-generation Cephalosporin
• By Type
  • Branded Cephalosporin Drugs
  • Generic Cephalosporin Drugs
• By Formulation
  • Oral
  • Tablets
  • Capsules
  • Liquid
  • Injection
• By Indication
  • Respiratory Tract Infection
  • Skin Infection
  • Ear Infection
  • Bacterial Infection
  • Urinary Tract Infection
  • Sexually Transmitted Infection
  • Sinus Infection
  • Surgical Prophylaxis
  • Others
  • Meningitis
  • Acute Abdomen Infection
  • Pelvic infection
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Regional Insights
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Merck & Co. Inc.
  • GlaxoSmithKline plc.
  • Pfizer Inc.
  • Allergan plc.
  • Abbott Laboratories
  • Basilea Pharmaceutica Ltd.
  • Sanofi S.A.
  • Hoffmann-La Roche AG
  • Lupin Limited
  • Teva Pharmaceutical Industries Ltd.
  • Braun Melsungen AG.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Generation
  • Market Snippet, By Type
  • Market Snippet, By Formulation
  • Market Snippet, By Indication
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Drivers
• Restraints
• PEST Analysis
• PORTER's Five Forces Analysis
• Market Opportunities
• Regulatory Scenario
• Key Developments
• Industry Trend

4. Global Cephalosporin Drugs Market, By Generation, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• First-Generation Cephalosporin
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Second-Generation Cephalosporin
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Third-Generation Cephalosporin
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Fourth-Generation Cephalosporin
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Fifth-Generation Cephalosporin
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

5. Global Cephalosporin Drugs Market, By Type, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Branded Cephalosporin Drugs
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Generic Cephalosporin Drugs
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

6. Global Cephalosporin Drugs Market, By Formulation, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Oral
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Tablets
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Capsules
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Liquid
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Injection
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

7. Global Cephalosporin Drugs Market, By Indication, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Respiratory Tract Infection
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Skin Infection
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Ear Infection
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Bacterial Infection
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Urinary Tract Infection
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Sexually Transmitted Infection
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Sinus Infection
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Surgical Prophylaxis
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Others
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Meningitis
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Acute Abdomen Infection
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Pelvic Infection
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

8. Global Cephalosporin Drugs Market, By Distribution Channel, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Retail Pharmacies
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Online Pharmacies
  • Market Share Analysis, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends

9. Global Cephalosporin Drugs Market, By Region, 2026-2033, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
  • Y-o-Y Growth Analysis, For Region, 2021 - 2033
• North America
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Generation, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Formulation, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Generation, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Formulation, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Generation, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Formulation, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Generation, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Formulation, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country, 2021 - 2033
  • Market Size and Forecast, By Generation, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Formulation, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Market Share Analysis, By Country/Region, 2025, 2028 and 2033 (%)
  • Y-o-Y Growth Analysis, For Country/Region, 2021 - 2033
  • Market Size and Forecast, By Generation, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Type, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Formulation, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
  • Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

10. Competitive Landscape

• Heat Map Analysis
  • Market Share Analysis (3x3 Matrix)
  • Company Profiles
  • Merck & Co. Inc.
  • Company Overview
  • Product Type Portfolio
  • Recent Developments/Updates
• GlaxoSmithKline plc.
  • Company Overview
  • Product Type Portfolio
  • Recent Developments/Updates
  • Pfizer Inc.
  • Company Overview
  • Product Type Portfolio
  • Recent Developments/Updates
• Allergan plc.
  • Company Overview
  • Product Type Portfolio
  • Recent Developments/Updates
  • Abbott Laboratories
  • Company Overview
  • Product Type Portfolio
  • Recent Developments/Updates
• Basilea Pharmaceutica Ltd.
  • Company Overview
  • Product Type Portfolio
  • Recent Developments/Updates
  • Sanofi S.A.
  • Company Overview
  • Product Type Portfolio
  • Recent Developments/Updates
• F. Hoffmann-La Roche AG
  • Company Overview
  • Product Type Portfolio
  • Recent Developments/Updates
  • Lupin Limited
  • Company Overview
  • Product Type Portfolio
  • Recent Developments/Updates
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Product Type Portfolio
  • Recent Developments/Updates
  • B. Braun Melsungen AG.
  • Company Overview
  • Product Type Portfolio
  • Recent Developments/Updates

11. Analyst Recommendation

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. Section

• References
• Research Methodology
• About Us and Sales Contact